US Patent

US9095706 — Self-test for analgesic product

Formulation · Assigned to Alza Corp · Expires 2033-02-03 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a self-test system for electrotransport drug delivery devices to prevent unintended delivery of a drug, such as fentanyl hydrochloride.

USPTO Abstract

Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.

Drugs covered by this patent

Patent Metadata

Patent number
US9095706
Jurisdiction
US
Classification
Formulation
Expires
2033-02-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Alza Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.